Waode Fifin Ervina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Waode Fifin Ervina has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amelia Nur Vidyanti
Universitas Gadjah Mada
1 shared publication - Astuti Prodjohardjono
Department of Neurology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Yogyakarta, Yogyakarta, Indonesia
1 shared publication - Farizky Martriano Humardani
Faculty of Medicine, Universitas Trunodjoyo Madura, Madura, Indonesia
1 shared publication - Helen Cyntia Mago
Immunology Program, Postgraduate School, Universitas Airlangga, Surabaya, Indonesia
1 shared publication - Lisa Thalia Mulyanata
Faculty of Medicine, University of Surabaya, Surabaya, Indonesia
1 shared publication - Valentinus Besin
Faculty of Medicine, University of Surabaya, Surabaya 60292, Indonesia
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by LIDSEN Publishing Inc in OBM Neurobiology
- Vol. 010 (03) , 1-13
The Role of Adaptive Immune Response in Alzheimer’s Disease: Focus on Amyloid Beta-Reactive T Cells and Amyloid Beta-Specific Antibodies
Alzheimer’s disease is one of the most prevalent neurodegenerative diseases among older people. Generally, there are two main pathologies of Alzheimer’s disease, including the accumulation of amyloid beta and the hyperphosphorylation of the microtubule-associated Tau protein in the brain. Recently, more studies have discovered that changes in the immune system can be one of the causes of amyloid-beta deposits. Amyloid-beta is a product of the breakdown of the glycoprotein amyloid precursor protein, a transmembrane protein that is cleaved by β-secretase and γ-secretase. In the brain, amyloid-beta deposits can trigger microglia activation, which helps eliminate the deposits. However, microglia activation may induce neuroinflammation by releasing pro-inflammatory cytokines and damage the blood-brain barrier, which can cause an influx of peripheral immune cells, including the adaptive immune system, into the brain. The role of the adaptive immune system in Alzheimer’s disease pathology is quite complicated and may alter due to aging. Aging can directly alter the immune system by reducing protective immunity through reduced production of naïve T cells and increased memory T cells. The increase in memory T cells, which have already recognized specific antigens, such as amyloid beta, may act as amyloid beta-reactive T cells and induce activation and release of amyloid beta-specific antibodies from B cells. This condition increases neuroinflammatory processes. Several drugs that directly target the immune system showed promising results as Alzheimer’s disease progressed. However, due to limited data, inconsistent results, and late adverse outcome effects, these drugs still require further research.
- 21 August 2026
- Published by LIDSEN Publishing Inc in OBM Neurobiology
- Vol. 010 (03) , 1-13
Open AccessThe Role of Adaptive Immune Response in Alzheimer’s Disease: Focus on Amyloid Beta-Reactive T Cells and Amyloid Beta-Specific Antibodies
Alzheimer’s disease is one of the most prevalent neurodegenerative diseases among older people. Generally, there are two main pathologies of Alzheimer’s disease, including the accumulation of amyloid beta and the hyperphosphorylation of the microtubule-associated Tau protein in the brain. Recently, more studies have discovered that changes in the immune system can be one of the causes of amyloid-beta deposits. Amyloid-beta is a product of the breakdown of the glycoprotein amyloid precursor protein, a transmembrane protein that is cleaved by β-secretase and γ-secretase. In the brain, amyloid-beta deposits can trigger microglia activation, which helps eliminate the deposits. However, microglia activation may induce neuroinflammation by releasing pro-inflammatory cytokines and damage the blood-brain barrier, which can cause an influx of peripheral immune cells, including the adaptive immune system, into the brain. The role of the adaptive immune system in Alzheimer’s disease pathology is quite complicated and may alter due to aging. Aging can directly alter the immune system by reducing protective immunity through reduced production of naïve T cells and increased memory T cells. The increase in memory T cells, which have already recognized specific antigens, such as amyloid beta, may act as amyloid beta-reactive T cells and induce activation and release of amyloid beta-specific antibodies from B cells. This condition increases neuroinflammatory processes. Several drugs that directly target the immune system showed promising results as Alzheimer’s disease progressed. However, due to limited data, inconsistent results, and late adverse outcome effects, these drugs still require further research.